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We performed a retrospective (n  121) and prospective (n  305) verification of the Cepheid Xpert Flu
assay to determine its performance characteristics. The overall sensitivity and specificity were 93% and 100%,
respectively. Nasopharyngeal specimen sensitivities were 100% for seasonal influenza A/H1 virus and influenza
A/H3 virus, 90% for influenza A/2009/H1N1 virus, and 95% for influenza B virus.
The introduction of influenza A/2009/H1N1 virus into our
communities has challenged clinical laboratories to consider
the most appropriate diagnostic tools for the laboratory
diagnosis of influenza (4). Rapid antigen tests are limited by
inferior sensitivity (2), while culture and molecular tests are
constrained by longer turnaround times. The recently FDA-
cleared Xpert Flu assay (Cepheid, Sunnyvale, CA) is a rapid,
random-access molecular test capable of detecting and differ-
entiating influenza A, influenza B, and influenza A/2009/H1N1
viruses from nasal wash fluid samples/aspirates and nasopha-
ryngeal (NP) swabs. The Xpert assay allows extraction, ampli-
fication, and detection to take place within a single-use dispos-
able cartridge.
We conducted a verification study using both retrospective
respiratory samples (multiple specimen types) and prospective
NP swabs to analyze the performance of the Xpert Flu assay.
The reference method was defined as our laboratory-derived
assay (LDA), for which 200 l of specimen was extracted using
the Total Nucleic Acid Isolation Kit on the MagNAPure
(Roche Applied Science, Indianapolis, IN) with amplification
and detection performed on the ABI 7500 or the ABI 7500
FAST (Life Technologies, Carlsbad, CA) using primer and
probe sequences previously described for influenza A (1) and
influenza B (3) viruses. The Xpert Flu assay was performed in
accordance with the manufacturer’s instructions for cleared
specimen types (nasal wash fluid samples/aspirates and NP
swabs). Noncleared specimens were tested directly from viral
transport medium without preprocessing.
The retrospective study included 121 samples collected be-
tween January 2006 and December 2010 and stored at 70°C.
Results were originally obtained using viral culture, xTAG
RVP (Luminex Molecular Diagnostics, Austin, TX), or the
LDA. All discrepant results (e.g., Xpert Flu negative, archived
positive) were retested using the reference LDA. The retro-
spective specimens consisted of NP swabs (n  75), broncho-
alveolar lavage fluid samples/wash fluid samples (n  33), NP
aspirates (n  4), tracheal aspirates (n  4), sputum samples
(n  3), and nasal wash fluid samples (n  2). Prospective
specimens consisted of 305 NP swabs collected from patients
presenting with influenza-like illness between December 2010
and February 2011 and tested by the reference LDA. All spec-
imens positive for influenza A virus were typed using the
Prodesse ProFAST assay (Gen-Probe, San Diego, CA) if a
type had not already been determined by routine testing using
the xTAG RVP assay. Starting in 2009, NP swabs were col-
lected using flocked swabs transported in Universal Transport
Medium (Becton Dickinson, Franklin Lakes, NJ). All other
specimens were tested in viral transport medium (Remel, Le-
nexa, KS). This study was approved by the University of North
Carolina Institutional Review Board.
Lower limits of detection (LLD) were determined using viral
stocks of seasonal influenza A/H1 virus and influenza B virus
quantified by and obtained from Advanced Biotechnologies (Co-
lumbia, MD) or viral stocks of influenza A/H3 virus and influenza
A/2009/H1N1 virus quantified by real-time reverse transcription
(RT)-PCR. Dilutions were tested in triplicate for 3 consecutive
days. In-house studies had previously determined the LLD of the
LDA to be 375 viral particles per ml (vpm) for influenza A/H1
virus and 860 vpm for influenza B virus. The LLD of Xpert Flu
were 1,000 vpm for seasonal influenza A/H1 virus, 3,570 vpm for
influenza A/H3 virus, 5,000 vpm for influenza A/2009/H1N1 virus,
and 860 vpm for influenza B virus. Of note, all replicates of 3,000
vpm of influenza A/2009/H1N1 virus were detected by the 2009/
H1N1 virus probe, but only 78% (7/9) were detected by the
influenza A virus probe. The Xpert software reports influenza A
virus probe-negative, 2009/H1N1 virus probe-positive samples as
invalid.
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TABLE 1. Statistical analysis of cycle threshold values of discrepant
samples from the prospective study
Test result n Mean CT (95% CI)a P value
Influenza A virus (all) 59 22.72 (21.33, 24.11)
Xpert positive 55 21.81 (20.62, 22.97) 0.0001
Xpert negative 4 35.29 (33.75, 36.84)
Influenza B virus (all) 57 23.42 (22.14, 24.70)
Xpert positive 54 22.81 (21.67, 23.95) 0.0001
Xpert negative 3 34.32 (31.88, 36.76)
a CT, cycle threshold; CI, confidence interval.
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Analytical specificity was determined using high-concen-
tration stocks of: Staphylococcus aureus (methicillin suscep-
tible and methicillin resistant), Staphylococcus epidermidis,
Streptococcus pyogenes, Streptococcus agalactiae, viridans
group streptococci, Streptococcus pneumoniae, Moraxella ca-
tarrhalis, Haemophilus influenzae, Bordetella pertussis, Bor-
detella parapertussis, Klebsiella pneumoniae, Pseudomonas
aeruginosa, oropharyngeal flora, nasal flora, adenovirus,
metapneumovirus, respiratory syncytial viruses A and B,
rhinovirus, enterovirus, and parainfluenza viruses 1, 2, and
3. No cross-reactivity was observed.
The retrospective verification included a broad spectrum of
respiratory samples (see above), of which 82 were positive for
seasonal influenza A/H1 virus (n  16), influenza A/H3 virus
(n  20), influenza A/2009/H1N1 virus (n  31), or influenza
B virus (n  15). Thirty-nine negative samples were also tested.
Sensitivity was 100% for seasonal influenza A/H1 virus, influ-
enza A/H3 virus, and influenza B virus. However, only 24
(77%) of 31 influenza A/2009/H1N1 virus-positive samples
were detected by the Xpert Flu assay. One of these discrepant
specimens was excluded, as it was not positive upon repeat
testing with the LDA; thus, the sensitivity for influenza A/2009/
H1N1 virus was 80% (24/30). The false-negative specimens
included NP swabs (n  3), tracheal aspirates (n  2), and a
bronchoalveolar lavage fluid sample (n  1). Specificity was
100%.
Prospective NP swabs were tested by Xpert Flu upon re-
ceipt. Residual patient specimen was kept at 4°C until addi-
tional testing was complete (LDA and Prodesse ProFAST)
(median, 5 days; range, 0 to 24 days). Of the 305 NP swabs, 116
were positive by the reference LDA for influenza A virus (n 
59) and influenza B virus (n  57). The 59 influenza A virus-
positive samples were typed using the Prodesse ProFAST
assay, and 46 (78%) contained influenza A/2009/H1N1 virus
and 13 (22%) contained influenza A/H3 virus. Seven samples
produced results that were discrepant between the two assays
in the prospective study. The Xpert Flu assay detected 55/59
(93%) influenza A virus-positive swabs and 54/57 (95%) influ-
enza B virus-positive swabs. The four influenza A virus-positive
NP specimens missed by Xpert Flu were all detected and typed
as influenza A/2009/H1N1 virus by the Prodesse ProFAST
assay. Specimens detected solely by the LDA had significantly
higher crossing threshold values than those positive by both
tests (Table 1). Thus, Xpert Flu false-negative results are likely
due to decreased analytical sensitivity relative to the reference
LDA. The Xpert Flu assay was 100% specific.
A summary of the sensitivity data for the verification study
described here can be found in Table 2. There was no statistically
significant difference between the combined sensitivity of NP
specimens and non-NP specimens (P  0.15), presumably due to
the low number of positive non-NP specimens. Our data show the
feasibility of testing non-NP specimens by the Xpert Flu assay,
though more studies are needed to determine if there is a differ-
ence in sensitivity. Interestingly, no invalid results were obtained
due to the lack of amplification of internal control, indicating that
no inhibition was observed in any specimen type. Specificity was
consistently 100% among all specimen types. Although the LDA
is more sensitive than the Xpert Flu assay for influenza A/2009/
H1N1 virus and influenza B virus, it is a traditional real-time
RT-PCR assay that requires extraction and batch processing.
During influenza season, we perform the LDA three or four times
a day, achieving a turnaround time of 8 to 24 h. This is an
unacceptable time to result, particularly for our emergency de-
partment patients. The Xpert Flu assay has a 2-min hands-on
time and a 76-min run time. It is random access and simple to
perform and provides clear results, allowing laboratory personnel
not proficient in molecular techniques to perform the test. The
combined ease of use and acceptable sensitivity of the Xpert Flu
assay make it an attractive approach to the rapid molecular diag-
nosis of influenza.
We acknowledge the kind generosity of Gen-Probe for providing the
Prodesse ProFAST reagents for this study.
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TABLE 2. Summary of sensitivity data by viral type
Specimens
% Sensitivity
Influenza A/H1 virus Influenza A/H3 virus Influenza A/2009/H1 virus Influenza B virus All types
Retrospective
All 100 (16/16)a 100 (20/20) 80 (24/30) 100 (15/15) 93 (75/81)
NP 100 (9/9) 100 (16/16) 86 (19/22) 100 (10/10) 95 (54/57)
Non-NP 100 (7/7) 100 (4/4) 63 (5/8) 100 (5/5) 88 (21/24)
Prospective (all NP) NDb (0/0) 100 (13/13) 91 (42/46) 95 (54/57) 94 (109/116)
Combined
All 100 (16/16) 100 (33/33) 87 (66/76) 96 (69/72) 93 (184/197)
NP 100 (9/9) 100 (29/29) 90 (61/68) 95 (59/62) 94 (158/168)
Non-NP 100 (7/7) 100 (4/4) 63 (5/8) 100 (10/10) 90 (26/29)
a The values in parentheses are ratios of Xpert-positive to LDA-positive specimens.
b ND, none detected.
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